Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06164730 · ClinicalTrials.gov registry record · Phase 1
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
A Phase 1 study of Heterozygous Familial Hypercholesterolemia and Premature Coronary Heart Disease, sponsored by Verve Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
- 18
- Study locations
NCT06164730 is a Phase 1 study of Heterozygous Familial Hypercholesterolemia and Premature Coronary Heart Disease that is actively recruiting participants, run by Verve Therapeutics. The registered enrollment target is 85 participants, below the 242-participant average among 4 other Heterozygous Familial Hypercholesterolemia trials with a reported enrollment target (65% lower). The trial reports 18 study locations across 5 states.
The verdict
NCT06164730, a Phase 1 study of Heterozygous Familial Hypercholesterolemia and Premature Coronary Heart Disease, is actively recruiting participants, sponsored by Verve Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
- 18
- Study locations
Study Summary
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.
Conditions Studied
Interventions
- DRUG VERVE-102
Study Locations (18)
Other
- Clinical Study Center - Adelaide
- Clinical Study Center - Melbourne
- Clinical Study Center - Sydney
- Clinical Study Center - Chicoutimi
- Clinical Study Center - Montreal
- Clinical Study Center - Toronto
- Clinical Study Center - Vancouver
- Clinical Study Center - Rehovot
- Clinical Study Center - Christchurch
- Clinical Study Center - Birmingham
- Clinical Study Center - Edinburgh
- Clinical Study Center - London
- Clinical Study Center - Manchester
- Clinical Study Center - Nottingham
Alabama
- Clinical Study Center - Dothan
North Carolina
- Clinical Study Center - High Point
Texas
- Clinical Study Center - DeSoto
Washington
- Clinical Study Center - Renton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2024-04-30 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06164730
The ClinicalTrials.gov registry entry for NCT06164730 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 4 other Heterozygous Familial Hypercholesterolemia trials with a reported enrollment target (65% lower). The listed sponsor is Verve Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Heterozygous Familial Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which VERVE-102 is the first listed.
NCT06164730 reports 18 study locations spanning 5 distinct geographic areas - top geographies include Other, Alabama, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06164730 about?
NCT06164730 is a clinical study titled "A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease". VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing...
What is the current status of trial NCT06164730?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2024-04-30. Estimated completion is 2027-08.
What conditions does trial NCT06164730 study?
This clinical trial studies the following conditions: Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease.
What interventions are being tested in trial NCT06164730?
The interventions under investigation include: VERVE-102 (DRUG).
Who is sponsoring clinical trial NCT06164730?
This trial is sponsored by Verve Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06164730 being conducted?
This trial has 18 study locations across Alabama, North Carolina, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heterozygous Familial Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction
COMPLETED · Phase 3
-
Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
COMPLETED · Phase 2
-
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
COMPLETED · Phase 3
-
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
COMPLETED · Phase 3
Explore more on PlainTrial
Heterozygous Familial Hypercholesterolemia
All registered trials for this condition
Premature Coronary Heart Disease
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.